In New Orleans, recent findings presented at the 2026 Scientific Sessions of the American Diabetes Association highlight the potential benefits of survodutide, a once-weekly injectable therapy. This treatment targets both glucagon and glucagon-like peptide-1 (GLP-1) receptors, showing promise for individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease.
Addressing Obesity and Metabolic Health
Obesity, a chronic and complex metabolic disease, affects approximately 40% of U.S. adults and is linked to serious health issues such as cardiovascular disease, diabetes, and liver conditions like MASLD. If untreated, MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH), leading to severe liver damage and increased cancer risk. Many patients face a significant unmet need for effective treatments that address both weight management and overall metabolic health.
The SYNCHRONIZE-1 trial, a phase 3 clinical study, evaluated survodutide’s efficacy in adults with overweight or obesity, with and without type 2 diabetes. Published in the New England Journal of Medicine, the trial demonstrated substantial weight loss, with participants losing up to 16.6% of body weight without compromising muscle mass. The treatment also reduced visceral fat by up to 34%, which is linked to insulin resistance and cardiovascular risk. Additionally, liver fat reductions of up to 63.1% were observed, highlighting survodutide’s potential to improve liver health in those at risk of MASH.
Potential for Broader Health Benefits
Lead author Dr. Carel le Roux emphasized the importance of treatments that improve overall metabolic health, noting that such improvements can reduce the risk of serious complications associated with obesity. The SYNCHRONIZE-MASLD trial further supports survodutide’s potential, showing that it may address metabolic dysfunction drivers by selectively reducing visceral and liver fat while supporting meaningful weight loss.
Researchers plan to continue advancing the SYNCHRONIZE trial with studies focused on obesity, liver health, and cardiovascular outcomes. They also aim to explore treatment approaches in underserved populations, including women and those with MASLD/MASH.
The ADA’s 2026 Scientific Sessions, held in New Orleans, is the world’s largest meeting focused on diabetes research, prevention, and care. It brings together leading physicians, scientists, and healthcare professionals to discuss cutting-edge research and treatment advancements.
Original reporting: KTBS 3 (Shreveport) — read the source article.
